Physician profile
Kevin Capp
NPI 1588800155
$6,302.68
in general payments reported to CMS, 2019-2025
36 companies · $969 in 2025
The $969 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $888 · 2020: $840 · 2021: $740 · 2022: $1,233 · 2023: $799 · 2024: $833 · 2025: $969.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,601.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $989.05 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $874.30 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $869.98 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $533.91 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $358.43 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Astellas Pharma US INC | $317.08 | 2019-2024 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $292.14 | 2019-2025 | Jardiance |
| Abbvie INC. | $258.15 | 2021-2025 | Ubrelvy |
| Nevro Corp. | $229.85 | 2022-2023 | Senza |
| Exact Sciences Corporation | $203.97 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $165.10 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $126.32 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $117.81 | 2019 | |
| Abbott Laboratories | $110.36 | 2022-2024 | Freestyle Libre 3, Octrode |
| Novartis Pharmaceuticals Corporation | $98.87 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $89.77 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $83.48 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $83.14 | 2021 | |
| Viatris Specialty LLC | $62.51 | 2025 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $58.81 | 2019-2025 | Eliquis, Camzyos |
| Boston Scientific Corporation | $48.33 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.17 | 2022 | |
| Currax Pharmaceuticals LLC | $39.61 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.37 | 2024-2025 | Xifaxan |
| Philips North America LLC | $27.78 | 2019-2021 | |
| Amgen INC. | $27.42 | 2019-2025 | Otezla, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.28 | 2025 | Caplyta |
| Genentech USA, INC. | $22.38 | 2020 | |
| Grt US Holding, INC. | $20.66 | 2022 | |
| Grifols USA, LLC | $14.57 | 2021 | |
| Phathom Pharmaceuticals, INC. | $14.47 | 2025 | Voquezna |
| Paratek Pharmaceuticals, INC. | $14.11 | 2024 | Nuzyra |
| Sanofi-Aventis U.S. LLC | $13.81 | 2020 | |
| Sanofi Pasteur INC. | $13.44 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.25 | 2019 | |
| Bardy Diagnostics, INC. | $10.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Capp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.